Skip Navigation


JAC Advance Access originally published online on February 11, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/3/487    most recent
dkg135v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lee, S. S.
Right arrow Articles by Abdo, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S. S.
Right arrow Articles by Abdo, A. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 487-491
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?

Samuel S. Lee* and Ayman A. Abdo

Liver Unit, University of Calgary, 3330 Hospital Dr NW, Calgary, Alberta, Canada T2N 4N1

Keywords: hepatitis C, peginterferon, predictability, treatment

The first 150 words of the full text of this article appear below.


   Introduction
 
The King of Babylon stood at the parting of the ways, to use divination:

He made his arrows bright, he consulted with images, he looked in the liver.

Ezekiel 21: 21

Twenty-six centuries later, things have changed: ancient people wanted to predict future possibilities by means of the liver, whereas now we want to predict the future of the liver by any possible means. Today, hepatitis C virus (HCV), which probably did not exist at the time of the Babylonian Empire,1 chronically infects 170 million people worldwide, and can lead to liver failure and hepatocellular carcinoma.2,3 A mere decade ago, the best antiviral therapies produced a long-term virological remission (sustained virological response, SVR) in only 5–10% of treated patients, but significant advances in treatment have increased the SVR rate almost 10-fold to 54–61%. These high response rates were obtained by modifying the standard interferon {alpha} by attaching a polyethylene glycol (PEG) . . . [Full Text of this Article]


   Pre-treatment predictors
 
Regular interferon-based therapies

Pegylated interferons

Predictors of response after initiation of therapy

Regular interferon and ribavirin combination therapy

Pegylated interferons


   Future directions
 

   Acknowledgements
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. Boulestin, N. Kamar, F. Legrand-Abravanel, K. Sandres-Saune, L. Alric, J.-P. Vinel, L. Rostaing, and J. Izopet
Convenient Biological Assay for Polyethylene Glycol-Interferons in Patients with Hepatitis C
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3610 - 3612.
[Abstract] [Full Text] [PDF]